Evolving CSU Management - An Interactive Learning Experience

Chronic Spontaneous Urticaria (CSU) can be unpredictable, persistent, and frustrating for patients and clinicians alike. Emerging data on remibrutinib, a next-generation oral BTK inhibitor, offers promising insights into targeted control of CSU symptoms including improvements in itch and overall disease burden. This Innovation Experience brings together two key clinical posters and expert video insights to help you quickly interpret the evidence and translate it into real-world treatment considerations.